RxDoctor Payments Data

Rajvinder Parmar, MD

Internal Medicine · Beachwood, OHNPI 1609038348

Payments from drug & device makers

$7,133in general payments, 2019–2025

Across 430 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$697
  • Amgen$656
  • AbbVie$575
  • Novo Nordisk$527
  • AstraZeneca$482
  • Lilly USA, LLC$383
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$7,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,133 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$57,896
Medicare patients
213
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$144,557
OzempicSemaglutide78$102,131
IngrezzaValbenazine Tosylate29$87,852
JardianceEmpagliflozin127$69,178
TrulicityDulaglutide41$41,913
JanuviaSitagliptin Phosphate65$38,332
MounjaroTirzepatide36$37,623
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,067
XareltoRivaroxaban56$22,696
CreonLipase/Protease/Amylase31$15,604
Atorvastatin Calcium647$15,387
Lurasidone Hcl52$13,817
FarxigaDapagliflozin Propanediol20$12,704
MyrbetriqMirabegron35$11,412
Amlodipine Besylate738$6,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$130$144,557413 claims
Novo NordiskOzempic$527$102,13178 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$383$84,079132 claims
Boehringer IngelheimJardiance$236$69,178127 claims
MerckJanuvia$134$38,33265 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$697$30,54356 claims
Johnson & JohnsonXarelto$360$22,69656 claims
AbbVieCreon$575$15,60431 claims
AstraZenecaFarxiga$482$12,70420 claims
Astellas Pharma US IncMyrbetriq$267$11,41235 claims
Sanofi-aventis U.S. LLCLantus$119$4,44861 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$37$2,485315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Beachwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →